Progressive Familial Intrahepatic Cholestasis

Study identifies predictors of long-term outcomes in rare liver disease

In patients with progressive familial intrahepatic cholestasis type 3 (PFIC3), specific genetic variations and their response to ursodeoxycholic acid (UDCA) therapy are critical factors that predict long-term outcomes, according to a study. Patients with ≥1 missense variation, positive canalicular expression of MDR3, and biliary phospholipid levels over 6.9% of total...